Nature Biotechnology's annual survey of public biotechnology companies shows that the ranks are thinning and profits are shrinking.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Burrill, G.S. Biotech Endures: Looking Back at 2002 and Ahead to 2003. Genomic Proteomic Technology (January/February, 2003).
Bouchie, A. Biotechs slimming down. Nat. Biotechnol. 20, 864, 2002.
Crocker, G. Endurance: the European biotechnology report 2003. (Ernst & Young, New York, NY, 2003).
Lahteenmaki, R. & Fletcher, E. Public Biotechnology 2001—the numbers. Nat. Biotechnol. 20, 551–555, 2002.
Hodgson, J. Future trends in biotechnology mergers and acquisitions. (Ernst & Young, New York, NY, 2002).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lähteenmäki, R., DeFrancesco, L. Public biotechnology 2002—the numbers. Nat Biotechnol 21, 607–612 (2003). https://doi.org/10.1038/nbt0603-607
Issue Date:
DOI: https://doi.org/10.1038/nbt0603-607